Evidence map›Paper›PMID 40682646›Full record

ReviewBulletin of experimental biology and medicine2025

Cell Therapy for Type 1 Diabetes Mellitus: a Review of Clinical Trials.

M I Danilevskii, O V Zakharova, N N Skaletskiy, Yu B Basok, S A Roumiantsev, A V Lyundup

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M I DanilevskiiNational Medical Research Center for Endocrinology, Ministry of Health of the Russian Federation, Moscow, Russia. midanilevsky@mail.ru.
O V ZakharovaI. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
N N SkaletskiyV. I. Shumakov National Medical Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation, Moscow, Russia.
Yu B BasokV. I. Shumakov National Medical Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation, Moscow, Russia.
S A RoumiantsevNational Medical Research Center for Endocrinology, Ministry of Health of the Russian Federation, Moscow, Russia.
A V LyundupNational Medical Research Center for Endocrinology, Ministry of Health of the Russian Federation, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The article provides a review of cell therapy strategies for type 1 diabetes mellitus that are closest to approval by regulatory authorities and implementation in clinical practice. The data from contemporary clinical trials studying the safety and efficacy of cell technologies in the treatment of type 1 diabetes mellitus are presented. The main approaches to replacement and immunomodulatory cell therapy are defined. The results of using insulin-producing cells, regulatory T lymphocytes, tolerogenic dendritic cells, and mesenchymal stromal cells are described. Non-pharmacological strategies for preventing the rejection of allogeneic cell products are considered. The limitations and possibilities of cell therapy strategies for type 1 diabetes mellitus are analyzed.

Indexed as

Cell- and Tissue-Based TherapyDiabetes Mellitus, Type 1Clinical Trials as TopicDendritic CellsHumansInsulin-Secreting CellsIslets of Langerhans TransplantationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationT-Lymphocytes, Regulatorycell therapy; type 1 diabetes mellitus; cell immunotherapy; CRISPR/Cas9

Identifiers

PMID40682646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.